Event: Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial Results

Wednesday, March 6, 2019

Time of Event: 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time

Telephone Dial in: toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally

Conference ID: 6089328

For more information about this event, please see the press release.

Read more

Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, March 6, 2019

San Francisco, CA (February 19, 2019) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its fourth quarter and year-end 2018 financial results on March 6, 2019 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.

Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally, and using conference ID 6089328.

The call will also be webcast live here, with a replay available at that link for 30 days.

About Kindred Biosciences
Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. KindredBio’s first approved drug is Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats.

Important Safety Information
Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves to apply and wash hands after. Avoid contact with treated cat for 2 hours following application.  The most common adverse reactions include application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. Please see the full Prescribing Information.

Contacts
For investor inquiries:
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438

For media inquiries:
Jeanene Timberlake
jtimberlake@rooneyco.com
(646) 770-8858

Event: Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit

Monday, February 25, 2019

Location: Bank of America Tower, One Bryant Park, 51st Floor, NY

Presentation time: 9:25 – 10:05 AM ET

Company Attendee: Richard Chin, CEO

Webcast URL: Click here

For more information about this event, please see the press release.

Read more

Event: Kindred Biosciences to Present at Barclays Global Healthcare Conference

Tuesday, March 12, 2019

Location: Loews Miami Beach Hotel, Miami Beach, FL

Presentation time: 2:05 – 2:30 PM ET

Company Attendee: Denise Bevers, President and COO

Webcast URL: Click here

For more information about this event, please see the press release.

Read more

Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference

SAN FRANCISCO, February 13, 2019 — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Bank of America Merrill Lynch (BAML) Animal Health Summit on February 25 in New York City and at the Barclays Global Healthcare Conference on March 12 in Miami.

During this time, investors will have the opportunity to discuss recent developments, including the launch of KindredBio’s first product, key therapeutic programs in development, and upcoming milestones.

Conference Details:
BAML Animal Health Summit
Date: Monday, February 25, 2019
KindredBio participant: Richard Chin, Chief Executive Officer
Presentation time: 9:25-10:05 AM ET
Location: Bank of America Tower, One Bryant Park, 51st Floor, NY
Webcast URL: Click here

Barclays Global Healthcare Conference
Date: Tuesday, March 12, 2019
KindredBio participant: Denise Bevers, President and Chief Operating Officer
Presentation time: 2:05-2:30 PM ET
Location: Loews Miami Beach Hotel, Miami Beach, FL
Webcast URL: Click here

An archived version of the above webcasts will be available for 30 days on the Company’s website.

About Kindred Biosciences
Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. KindredBio’s first approved drug is Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats.

Important Safety Information
Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves to apply and wash hands after. Avoid contact with treated cat for 2 hours following application.  The most common adverse reactions include application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. Please see the full Prescribing Information.

Contact
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438